The National Heart, Lung, and Blood Institute (NHLBI) awarded a 4-year, $846,536 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. This grant supports research to characterize the role of the RPS6KB1 protein in the pathological transition from adaptive cardiac hypertrophy to heart failure. Key objectives include elucidating the mechanisms of RPS6KB1 phosphorylation by ERK and ubiquitination, and evaluating their implications for hypertensive heart disease and heart failure development using mouse models and primary cardiomyocyte cultures. The research aims to advance the understanding of hypertensive heart disease and inform the development of novel therapeutic interventions.
Generated 3/4/25, 5:37 AM